alexa Treatment Guideline for Advanced NSCLC Based on Driver Gene Mutations | Open Access Journals
ISSN: 2157-7412
Journal of Genetic Syndromes & Gene Therapy
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Treatment Guideline for Advanced NSCLC Based on Driver Gene Mutations

Kunihiko Kobayashi* and Koichi Hagiwara

Department of Respiratory Medicine, Saitama Medical University International Medical Center, Japan

*Corresponding Author:
Kunihiko Kobayashi
Department of Respiratory Medicine
Saitama Medical University International Medical Center
1397-1 Yamane, Hidaka City, 350-1298 Japan
Tel: +81-42-984-4667
Fax: +81-42-984-4667
E-mail: [email protected]

Received date: October 16, 2013; Accepted date:Junuary 17, 2014; Published date: Junuary 24, 2014

Citation: Kobayashi K, Hagiwara K (2014) Treatment Guideline for Advanced NSCLC Based on Driver Gene Mutations. J Genet Syndr Gene Ther 5: 212. doi:10.4172/2157-7412.1000212

Copyright: © 2014 Kobayashi K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Genetic Syndromes & Gene Therapy

In 2004, three groups of researchers retrospectively found a close relationship between epidermal growth factor (EGFR) gene mutations and efficacy of the EGFR-tyrosine kinase inhibitor (TKI) used in molecularly targeted therapy in non-small cell lung cancer (NSCLC) [1-3]. Since 2009, prospective randomized Phase 3 studies clarified that progression free survival (PFS) with use of EGFR-TKI was superior to that of cytotoxic chemotherapies for advanced NSCLC patients with EGFR mutations [4-7]. Next, in 2007, echinoderm microtubuleassociated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion gene was found to be another driver gene mutation of NSCLC, [8] and an ALK inhibitor, crizotinib, has been established to be active in terms of efficacy and PFS [9]. Both EGFR-TKI and ALK inhibitors are considered to have a positive effect on survival [10,11]. These suggest that the time for personalized treatments for advanced NSCLC has arrived. Furthermore, the results of Lung Cancer Mutation Consortium and other studies have clarified incidences of EGFR, ALK, KRAS, Pi3KCA, BRAF and other mutations [12], and might give chances of new targeted therapies. However, the majority of treatment guidelines for advanced NSCLC employ an old fashioned decision-tree (Figure 1A), in which the first decision step is histology (non-squamous cell carcinoma vs. squamous cell carcinoma) and, in the case of nonsquamous cell carcinoma, the second decision step is detecting EGFR mutations and ALK fusion mutations.

First, biomarker tests should predict treatment benefit more precisely than a histological examination. EGFR mutation tests have proven to be reliable for use in clinical practice [13]. In particular, EGFR mutation testing as a biomarker has attained high levels of predictability, reliability, and feasibility, and can be performed with practical cost [14-16]. Second, histological examination is only modestly reliable; in the discrimination between non-squamous cell carcinoma and squamous cell carcinoma, inter-pathologists’ correlation was found to be modest (κ=0.55) [17]. Therefore, in Japan, where approximately 50,000 patients were newly diagnosed as NSCLC in 2011, approximately 48,000 tests for EGFR mutations were performed, [16] indicating that most patients in Japan with NSCLC were screened. The cost of about 200 US dollars for the test is covered by national health insurance. In contrast, the infrastructure for testing EML4-ALK fusion genes is still being developed [18]. EML4-ALK fusion genes clearly predict clinical benefit with crizotinib treatment [9,11]. Nevertheless, there is no allpurpose testing procedure that has been established. Fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC) need big tissue samples, indicating that there is some problem in terms of feasibility of sampling for advanced NSCLC, which has no indication for operation. Reverse transcription PCR (RT-PCR) for EML4-ALK mutations also has modest feasibility because of the need for adequate quantities of RNA immediately after getting clinical samples. Furthermore, there is some inconsistency among results by FISH, IHC and RT-PCR, [18] such as the level of reliability. Currently, FISH is more validated than IHC and RT-PCR [19]; however, FISH is the most expensive test and may not be suitable for massive screening. Therefore, the actual treatment guideline for advanced NSCLC at present in Japan as well as in Italy [20] designates EGFR testing as the first step, histological examination (non-squamous cell carcinoma vs. squamous cell carcinoma) as the second step, and, in the case of non-squamous cell carcinoma, testing for ALK fusion genes (Figure 1B) is the 3rd decision step.

genetic-syndromes-gene-therapy-Present-guideline

Figure 1: A: Majority of treatment guidelines for advanced NSCLC. B: Present guideline for advanced NSCLC in Japan and Italy. C: Future guideline for advanced NSCLC based on driver gene mutations.

In future, when we get an easy, reliable and not-expensive screening test to investigate all of the “druggable” mutations, which have specific inhibitors, a final guideline having the first step of testing druggable mutations and, thereafter, the second step of histological examination will be born (Figure 1C). The value of testing for other driver gene mutations will be more appreciated in future treatment guidelines.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11586
  • [From(publication date):
    January-2014 - Aug 18, 2017]
  • Breakdown by view type
  • HTML page views : 7819
  • PDF downloads :3767
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords